Comparative Pharmacology
Head-to-head clinical analysis: DRALSERP versus RAPLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRALSERP versus RAPLON.
DRALSERP vs RAPLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depletes monoamines (serotonin, norepinephrine, dopamine) from central and peripheral nerve terminals by binding to and inhibiting the vesicular monoamine transporter 2 (VMAT2), impairing storage and leading to enzymatic degradation.
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
0.25 mg orally once daily; may increase by 0.25 mg every 2 weeks to a maximum of 1 mg daily in divided doses.
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
None Documented
None Documented
Terminal elimination half-life is 45 to 50 hours; clinically significant as drug accumulates with repeated dosing, requiring careful titration.
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Primarily hepatic metabolism to inactive metabolites; less than 1% excreted unchanged in urine; approximately 10% eliminated in feces.
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Category C
Category C
Antihypertensive
Antihypertensive